Oral Glyceryl Triacetate (GTA) in Newborns With Canavan
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Canavan disease is caused by Aspartoacylase deficiency. There is no treatment for the
disease, but there is a food additive that includes acetate . We suggest an early treatment
with acetate and a neurologic evaluation, including MRI, after 4 months of treatment. In any
case the treatment will be stopped at the age of 22 months, when myelinization is ended.